Human Olfactory Mucosa Multipotent Mesenchymal Stromal Cells Promote Survival, Proliferation, and Differentiation of Human Hematopoietic Cells
Overview
Affiliations
Multipotent mesenchymal stromal cells (MSCs) from the human olfactory mucosa (OM) are cells that have been proposed as a niche for neural progenitors. OM-MSCs share phenotypic and functional properties with bone marrow (BM) MSCs, which constitute fundamental components of the hematopoietic niche. In this work, we investigated whether human OM-MSCs may promote the survival, proliferation, and differentiation of human hematopoietic stem cells (HSCs). For this purpose, human bone marrow cells (BMCs) were co-cultured with OM-MSCs in the absence of exogenous cytokines. At different intervals, nonadherent cells (NACs) were harvested from BMC/OM-MSC co-cultures, and examined for the expression of blood cell markers by flow cytometry. OM-MSCs supported the survival (cell viability >90%) and proliferation of BMCs, after 54 days of co-culture. At 20 days of co-culture, flow cytometric and microscopic analyses showed a high percentage (73%) of cells expressing the pan-leukocyte marker CD45, and the presence of cells of myeloid origin, including polymorphonuclear leukocytes, monocytes, basophils, eosinophils, erythroid cells, and megakaryocytes. Likewise, T (CD3), B (CD19), and NK (CD56/CD16) cells were detected in the NAC fraction. Colony-forming unit-granulocyte/macrophage (CFU-GM) progenitors and CD34(+) cells were found, at 43 days of co-culture. Reverse transcriptase-polymerase chain reaction (RT-PCR) studies showed that OM-MSCs constitutively express early and late-acting hematopoietic cytokines (i.e., stem cell factor [SCF] and granulocyte- macrophage colony-stimulating factor [GM-CSF]). These results constitute the first evidence that OM-MSCs may provide an in vitro microenvironment for HSCs. The capacity of OM-MSCs to support the survival and differentiation of HSCs may be related with the capacity of OM-MSCs to produce hematopoietic cytokines.
Dabrowska S, Andrzejewska A, Janowski M, Lukomska B Front Immunol. 2021; 11:591065.
PMID: 33613514 PMC: 7893976. DOI: 10.3389/fimmu.2020.591065.
Are nestin-positive mesenchymal stromal cells a better source of cells for CNS repair?.
Lindsay S, Barnett S Neurochem Int. 2016; 106:101-107.
PMID: 27498150 PMC: 5455984. DOI: 10.1016/j.neuint.2016.08.001.
Isolation and characterization of multipotent mesenchymal stem cells in nasal polyps.
Cho J, Park J, Kang J, Kim S, Park I, Lee H Exp Biol Med (Maywood). 2014; 240(2):185-93.
PMID: 25294891 PMC: 4935324. DOI: 10.1177/1535370214553898.
Differential marker expression by cultures rich in mesenchymal stem cells.
Wetzig A, Alaiya A, Al-Alwan M, Pradez C, Pulicat M, Al-Mazrou A BMC Cell Biol. 2013; 14:54.
PMID: 24304471 PMC: 4235221. DOI: 10.1186/1471-2121-14-54.
Cell-based therapy for prevention and reversal of myocardial remodeling.
Karantalis V, Balkan W, Schulman I, Hatzistergos K, Hare J Am J Physiol Heart Circ Physiol. 2012; 303(3):H256-70.
PMID: 22636682 PMC: 3423164. DOI: 10.1152/ajpheart.00221.2012.